Prescrire Int. 2014 May;23(149):136-8.
Drug packaging is important both in protecting and informing patients. Some improvements were made in 2013, but many of the products examined by Prescrire still had poor-quality or even dangerous packaging. Problem packaging is a major concern for patients who are more vulnerable to adverse effects, particularly children and pregnant women. Several problems were noted with products intended for self-medication (umbrella brands), oral solutions sold with dosing devices, and injectable drugs. Looking back at 20 years of Red Cards that Prescrire has issued to products with dangerous packaging reveals several improvements, but too many dangers persist. Urgent action needs to be taken by regulatory agencies and drug companies: patient leaflets must be more explicit with regard to adverse effects, especially those of nonsteroidal anti-inflammatory drugs during pregnancy; accidental ingestion by children must be prevented; and companies must design safer dosing devices. Healthcare professionals and patients must remain vigilant and report all packaging issues to the relevant authorities.
药品包装对于保护患者以及向患者提供信息都很重要。2013年有了一些改进，但《处方笺》审查的许多产品包装质量仍然很差，甚至存在危险。问题包装是更容易受到不良反应影响的患者（尤其是儿童和孕妇）的主要担忧。非处方药（总品牌）、随给药装置出售的口服溶液以及注射用药物都存在若干问题。回顾《处方笺》过去20年发给包装危险产品的“红牌”可以发现有一些改进，但仍存在太多危险。监管机构和制药公司必须立即采取行动：患者说明书必须更明确地说明不良反应，尤其是孕期非甾体抗炎药的不良反应；必须防止儿童意外摄入；公司必须设计更安全的给药装置。医疗专业人员和患者必须保持警惕，向有关当局报告所有包装问题。
